GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc.

Dr. Phillip Gomez, Former Director, Vaccine Production at the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH) Vaccine Research Center (VRC), has joined PRTM as a principal in the firm's Biodefense and Public Health Practice.

GenVec, Inc. (Nasdaq:GNVC) announced that results from multiple ongoing clinical trials utilizing its adenovector vaccine technologies were presented yesterday at the AIDS Vaccine 2007 Conference taking place in Seattle, Washington this week.

Leiden, The Netherlands, September 26, 2006 - Dutch biotechnology company Crucell N.V.

Study to Assess Effectiveness of a Vaccine Utilizing Boost Based on GenVec's Adenovector Technology and Proprietary Cell Line to Treat Patients Infected with Most Common Strains of HIV GenVec, Inc.